Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Brain Tumors of Glial Origin.

Waker CA, Lober RM.

Adv Exp Med Biol. 2019;1190:281-297. doi: 10.1007/978-981-32-9636-7_18. Review.

PMID:
31760651
2.

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.

Akyerli CB, Yüksel Ş, Can Ö, Erson-Omay EZ, Oktay Y, Coşgun E, Ülgen E, Erdemgil Y, Sav A, von Deimling A, Günel M, Yakıcıer MC, Pamir MN, Özduman K.

J Neurosurg. 2018 Apr;128(4):1102-1114. doi: 10.3171/2016.11.JNS16973. Epub 2017 Jun 16.

PMID:
28621624
3.

New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.

Karsy M, Guan J, Cohen AL, Jensen RL, Colman H.

Curr Neurol Neurosci Rep. 2017 Feb;17(2):19. doi: 10.1007/s11910-017-0722-5. Review.

PMID:
28271343
4.

Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.

Zacher A, Kaulich K, Stepanow S, Wolter M, Köhrer K, Felsberg J, Malzkorn B, Reifenberger G.

Brain Pathol. 2017 Mar;27(2):146-159. doi: 10.1111/bpa.12367. Epub 2016 Apr 19.

PMID:
26919320
5.

Biomarker-driven diagnosis of diffuse gliomas.

Appin CL, Brat DJ.

Mol Aspects Med. 2015 Nov;45:87-96. doi: 10.1016/j.mam.2015.05.002. Epub 2015 May 21. Review.

PMID:
26004297
6.

ATRX immunostaining predicts IDH and H3F3A status in gliomas.

Ebrahimi A, Skardelly M, Bonzheim I, Ott I, Mühleisen H, Eckert F, Tabatabai G, Schittenhelm J.

Acta Neuropathol Commun. 2016 Jun 16;4(1):60. doi: 10.1186/s40478-016-0331-6.

7.

The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.

Lee Y, Koh J, Kim SI, Won JK, Park CK, Choi SH, Park SH.

Acta Neuropathol Commun. 2017 Aug 29;5(1):62. doi: 10.1186/s40478-017-0465-1.

8.

Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.

Macaulay RJ.

Cancer Control. 2015 Apr;22(2):200-5. Review.

PMID:
26068765
9.

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT.

Oncotarget. 2012 Oct;3(10):1194-203.

10.

Copy Number Profiling of Brazilian Astrocytomas.

Bidinotto LT, Torrieri R, Mackay A, Almeida GC, Viana-Pereira M, Cruvinel-Carloni A, Spina ML, Campanella NC, Pereira de Menezes W, Clara CA, Becker AP, Jones C, Reis RM.

G3 (Bethesda). 2016 Jul 7;6(7):1867-78. doi: 10.1534/g3.116.029884.

11.

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y.

Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.

12.

Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.

Malzkorn B, Reifenberger G.

Pathologe. 2019 Jun;40(Suppl 1):9-17. doi: 10.1007/s00292-019-0581-8. Review.

PMID:
31025086
13.

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT.

Clin Cancer Res. 2012 May 1;18(9):2490-501. doi: 10.1158/1078-0432.CCR-11-2977. Epub 2012 Mar 13.

14.

Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.

Brendle C, Hempel JM, Schittenhelm J, Skardelly M, Tabatabai G, Bender B, Ernemann U, Klose U.

Clin Neuroradiol. 2018 Sep;28(3):421-428. doi: 10.1007/s00062-017-0590-z. Epub 2017 May 9.

PMID:
28488024
15.

TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.

Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Chan AK, Park CK, Fung KM, Hassell L.

Crit Rev Oncol Hematol. 2017 Dec;120:1-9. doi: 10.1016/j.critrevonc.2017.09.013. Epub 2017 Oct 3. Review.

PMID:
29198322
16.

DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.

Paul Y, Mondal B, Patil V, Somasundaram K.

Clin Epigenetics. 2017 Apr 4;9:32. doi: 10.1186/s13148-017-0331-9. eCollection 2017.

17.

IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.

Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N.

Neuro Oncol. 2016 Oct;18(10):1402-12. doi: 10.1093/neuonc/now061. Epub 2016 Apr 25.

18.

Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.

Yang P, Cai J, Yan W, Zhang W, Wang Y, Chen B, Li G, Li S, Wu C, Yao K, Li W, Peng X, You Y, Chen L, Jiang C, Qiu X, Jiang T; CGGA project.

Neuro Oncol. 2016 Aug;18(8):1099-108. doi: 10.1093/neuonc/now021. Epub 2016 Mar 7.

19.

Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma.

Fan HC, Chen CM, Chi CS, Tsai JD, Chiang KL, Chang YK, Lin SZ, Harn HJ.

Int J Mol Sci. 2019 Jan 8;20(1). pii: E200. doi: 10.3390/ijms20010200. Review.

20.

Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.

Delfanti RL, Piccioni DE, Handwerker J, Bahrami N, Krishnan A, Karunamuni R, Hattangadi-Gluth JA, Seibert TM, Srikant A, Jones KA, Snyder VS, Dale AM, White NS, McDonald CR, Farid N.

J Neurooncol. 2017 Dec;135(3):601-609. doi: 10.1007/s11060-017-2613-7. Epub 2017 Sep 4. Erratum in: J Neurooncol. 2017 Sep 13;:.

Supplemental Content

Support Center